GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Total Liabilities
中文

Regnum (Regnum) Total Liabilities

: $1.85 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Regnum's Total Liabilities for the quarter that ended in Mar. 2023 was $1.85 Mil.

Regnum's quarterly Total Liabilities declined from Sep. 2022 ($2.07 Mil) to Dec. 2022 ($2.03 Mil) and declined from Dec. 2022 ($2.03 Mil) to Mar. 2023 ($1.85 Mil).

Regnum's annual Total Liabilities increased from Dec. 2020 ($0.06 Mil) to Dec. 2021 ($1.87 Mil) and increased from Dec. 2021 ($1.87 Mil) to Dec. 2022 ($2.03 Mil).


Regnum Total Liabilities Historical Data

The historical data trend for Regnum's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regnum Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Premium Member Only - - 0.06 1.87 2.03

Regnum Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Liabilities Take a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 2.21 2.07 2.03 1.85

Regnum Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Regnum's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.025+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.03

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=0.865--1.161
=2.03

Regnum's Total Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.847+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.85

Total Liabilities=Total Assets (Q: Mar. 2023 )-Total Equity (Q: Mar. 2023 )
=0.496--1.351
=1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regnum Total Liabilities Related Terms

Thank you for viewing the detailed overview of Regnum's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Regnum (Regnum) Business Description

Traded in Other Exchanges
N/A
Address
600 Third Avenue, 19th Floor, New York, NY, USA, 10016
Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.

Regnum (Regnum) Headlines

No Headlines